Abstract:The Ebola virus (EBOV) has emerged as a significant global health concern, notably during the 2013–2016 outbreak in West Africa. Despite the clinical approval of two EBOV antibody drugs, there is an urgent need for more diverse and effective antiviral drugs, along with comprehensive understanding of viral-host interactions. In this study, we harnessed a biologically contained EBOVΔVP30-EGFP cell culture model which could recapitulate the entire viral life cycle, to conduct a genome-wide CRISPR/Cas9 screen. Through this, we identified PIK3C3 (phosphatidylinositide 3-kinase) and SLC39A9 (zinc transporter) as crucial host factors for EBOV infection. Genetic depletion of SLC39A9 and PIK3C3 lead to reduction of EBOV entry, but not impact viral genome replication, suggesting that SLC39A9 and PIK3C3 act as entry factors, facilitating viral entry into host cells. Moreover, PIK3C3 kinase activity is indispensable for the internalization of EBOV virions, presumably through the regulation of endocytic and autophagic membrane traffic, which has been previously recognized as essential for EBOV internalization. Notably, our study demonstrated that PIK3C3 kinase inhibitor could effectively block EBOV infection, underscoring PIK3C3 as a promising drug target. Furthermore, biochemical analysis showed that recombinant SLC39A9 protein could directly bind viral GP protein, which further promotes the interaction of viral GP protein with cellular receptor NPC1. These findings suggests that SLC39A9 plays dual roles in EBOV entry. Initially, it serves as an attachment factor during the early entry phase by engaging with the viral GP protein. Subsequently, SLC39A9 functions an adaptor protein, facilitating the interaction between virions and the NPC1 receptor during the late entry phase, prior to cathepsin cleavage on the viral GP. In summary, this study offers novel insights into virus-host interactions, contributing valuable information for the development of new therapies against EBOV infection. Ebola virus (EBOV) remains a significant global health threat. The limited availability of high-containment (BSL-4) facilities hinders our understanding of the interaction of virus with host cells and the development of effective treatments. To address this, we utilized a biologically contained EBOVΔVP30-EGFP model to identify critical host factors necessary for EBOV infection through a genome-wide CRISPR/Cas9 screen conducted at BSL-2 lab. Our study revealed that two proteins, PIK3C3 and SLC39A9, are essential for the virus to enter host cells. We found that PIK3C3 is required for EBOV endosomal trafficking, and inhibiting its kinase activity can significantly reduce infection, making it a promising target for antiviral therapy. Additionally, we discovered that SLC39A9 facilitates viral entry by interacting with the viral glycoprotein (GP) and enhancing its binding to the cell's NPC1 receptor, rather than through its usual role in zinc transport. These findings offer new insights into how EBOV enters cells and highlight potential targets for developing therapies to combat Ebola virus infection.

Utility of primary cells to examine NPC1 receptor expression in Mops condylurus, a potential Ebola virus reservoir

Tolerance and Persistence of Ebola Virus in Primary Cells from Mops condylurus, a Potential Ebola Virus Reservoir

Dendritic Cells Generated From Mops condylurus, a Likely Filovirus Reservoir Host, Are Susceptible to and Activated by Zaire Ebolavirus Infection

Selective replication and vertical transmission of Ebola virus in experimentally infected Angolan free-tailed bats

Transcriptional Analysis of Lymphoid Tissues from Infected Nonhuman Primates Reveals the Basis for Attenuation and Immunogenicity of an Ebola Virus Encoding a Mutant VP35 Protein

The Lifecycle of the Ebola Virus in Host Cells.

Stimulation of Ebola virus production from persistent infection through activation of the Ras/MAPK pathway

Adipose Tissues from Human and Bat-Derived Cell Lines Support Ebola Virus Infection

Marburg and Ebola Virus Infections Elicit a Complex, Muted Inflammatory State in Bats

Genome-wide CRISPR/Cas9 screen identifies SLC39A9 and PIK3C3 as crucial entry factors for Ebola virus infection

Differential Sensitivity of Bat Cells to Infection by Enveloped RNA Viruses: Coronaviruses, Paramyxoviruses, Filoviruses, and Influenza Viruses

A Bayesian analysis of birth pulse effects on the probability of detecting Ebola virus in fruit bats

Immunophenotyping Monocytes, Macrophages and Granulocytes in the Pteropodid Bat Eonycteris Spelaea.

Early Transcriptional Changes within Liver, Adrenal Gland, and Lymphoid Tissues Significantly Contribute to Ebola Virus Pathogenesis in Cynomolgus Macaques

Activating NK- receptors, homing selectins and inhibitory Siglecs recognize EBOLA-GP and HPV-L1NK

Single-cell Transcriptome Analysis of the in Vivo Response to Viral Infection in the Cave Nectar Bat Eonycteris Spelaea.

Histology, immunohistochemistry, and in situ hybridization reveal overlooked Ebola virus target tissues in the Ebola virus disease guinea pig model

Asymptomatic Infection of Marburg Virus Reservoir Bats Is Explained by a Strategy of Immunoprotective Disease Tolerance

Single-Cell Profiling of Ebola Virus Disease In Vivo Reveals Viral and Host Dynamics

Direct Intracellular Visualization of Ebola Virus-Receptor Interaction by In Situ Proximity Ligation

A novel in vitro system of supported planar endosomal membranes (SPEMs) reveals an enhancing role for cathepsin B in the final stage of Ebola virus fusion and entry